- Home
- PK vs AMRX Comparison
PK vs AMRX Comparison
Compare PK & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- AMRX
- Stock Information
- Founded
- PK 1946
- AMRX 2002
- Country
- PK United States
- AMRX United States
- Employees
- PK N/A
- AMRX N/A
- Industry
- PK Real Estate Investment Trusts
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- AMRX Health Care
- Exchange
- PK Nasdaq
- AMRX Nasdaq
- Market Cap
- PK 2.5B
- AMRX 2.4B
- IPO Year
- PK N/A
- AMRX N/A
- Fundamental
- Price
- PK $10.45
- AMRX $7.55
- Analyst Decision
- PK Buy
- AMRX Strong Buy
- Analyst Count
- PK 11
- AMRX 5
- Target Price
- PK $15.15
- AMRX $10.80
- AVG Volume (30 Days)
- PK 4.8M
- AMRX 2.1M
- Earning Date
- PK 05-05-2025
- AMRX 05-02-2025
- Dividend Yield
- PK 9.61%
- AMRX N/A
- EPS Growth
- PK 45.67
- AMRX N/A
- EPS
- PK 0.61
- AMRX N/A
- Revenue
- PK $2,602,000,000.00
- AMRX $2,830,186,000.00
- Revenue This Year
- PK $2.76
- AMRX $10.49
- Revenue Next Year
- PK $3.39
- AMRX $7.00
- P/E Ratio
- PK $17.09
- AMRX N/A
- Revenue Growth
- PK N/A
- AMRX 13.42
- 52 Week Low
- PK $8.27
- AMRX $5.18
- 52 Week High
- PK $16.58
- AMRX $9.48
- Technical
- Relative Strength Index (RSI)
- PK 54.89
- AMRX 49.10
- Support Level
- PK $9.89
- AMRX $7.15
- Resistance Level
- PK $10.50
- AMRX $7.59
- Average True Range (ATR)
- PK 0.32
- AMRX 0.31
- MACD
- PK 0.12
- AMRX 0.03
- Stochastic Oscillator
- PK 89.80
- AMRX 46.89
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.